154 related articles for article (PubMed ID: 10801813)
21. Aggrecan-versican-neurocan family proteoglycans.
Margolis RU; Margolis RK
Methods Enzymol; 1994; 245():105-26. PubMed ID: 7539091
[No Abstract] [Full Text] [Related]
22. The globular domains of PG-M/versican modulate the proliferation-apoptosis equilibrium and invasive capabilities of tumor cells.
Cattaruzza S; Schiappacassi M; Kimata K; Colombatti A; Perris R
FASEB J; 2004 Apr; 18(6):779-81. PubMed ID: 14977887
[TBL] [Abstract][Full Text] [Related]
23. Alternative splicing in the aggrecan G3 domain influences binding interactions with tenascin-C and other extracellular matrix proteins.
Day JM; Olin AI; Murdoch AD; Canfield A; Sasaki T; Timpl R; Hardingham TE; Aspberg A
J Biol Chem; 2004 Mar; 279(13):12511-8. PubMed ID: 14722076
[TBL] [Abstract][Full Text] [Related]
24. cDNA cloning of PG-M, a large chondroitin sulfate proteoglycan expressed during chondrogenesis in chick limb buds. Alternative spliced multiforms of PG-M and their relationships to versican.
Shinomura T; Nishida Y; Ito K; Kimata K
J Biol Chem; 1993 Jul; 268(19):14461-9. PubMed ID: 8314802
[TBL] [Abstract][Full Text] [Related]
25. Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44.
Kawashima H; Hirose M; Hirose J; Nagakubo D; Plaas AH; Miyasaka M
J Biol Chem; 2000 Nov; 275(45):35448-56. PubMed ID: 10950950
[TBL] [Abstract][Full Text] [Related]
26. Versican G3 domain promotes blood coagulation through suppressing the activity of tissue factor pathway inhibitor-1.
Zheng PS; Reis M; Sparling C; Lee DY; La Pierre DP; Wong CK; Deng Z; Kahai S; Wen J; Yang BB
J Biol Chem; 2006 Mar; 281(12):8175-82. PubMed ID: 16431924
[TBL] [Abstract][Full Text] [Related]
27. Localization of aggrecan and versican in the developing rat central nervous system.
Popp S; Andersen JS; Maurel P; Margolis RU
Dev Dyn; 2003 May; 227(1):143-9. PubMed ID: 12701107
[TBL] [Abstract][Full Text] [Related]
28. Distinct interaction of versican/PG-M with hyaluronan and link protein.
Matsumoto K; Shionyu M; Go M; Shimizu K; Shinomura T; Kimata K; Watanabe H
J Biol Chem; 2003 Oct; 278(42):41205-12. PubMed ID: 12888576
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal antibodies directed against epitopes within the core protein structure of the large aggregating proteoglycan (aggrecan) from the swarm rat chondrosarcoma.
Calabro A; Hascall VC; Caterson B
Arch Biochem Biophys; 1992 Nov; 298(2):349-60. PubMed ID: 1384430
[TBL] [Abstract][Full Text] [Related]
30. Expression of a chondroitin sulfate proteoglycan, versican (PG-M), during development of rat cornea.
Koga T; Inatani M; Hirata A; Inomata Y; Zako M; Kimata K; Oohira A; Gotoh T; Mori M; Tanihara H
Curr Eye Res; 2005 Jun; 30(6):455-63. PubMed ID: 16020278
[TBL] [Abstract][Full Text] [Related]
31. Alternative splicing of the unique "PLUS" domain of chicken PG-M/versican is developmentally regulated.
Zako M; Shinomura T; Kimata K
J Biol Chem; 1997 Apr; 272(14):9325-31. PubMed ID: 9083069
[TBL] [Abstract][Full Text] [Related]
32. Structure and function of aggrecan.
Kiani C; Chen L; Wu YJ; Yee AJ; Yang BB
Cell Res; 2002 Mar; 12(1):19-32. PubMed ID: 11942407
[TBL] [Abstract][Full Text] [Related]
33. Limited growth of severed CNS axons after treatment of adult rat brain with hyaluronidase.
Moon LD; Asher RA; Fawcett JW
J Neurosci Res; 2003 Jan; 71(1):23-37. PubMed ID: 12478611
[TBL] [Abstract][Full Text] [Related]
34. Versican V2 is a major extracellular matrix component of the mature bovine brain.
Schmalfeldt M; Dours-Zimmermann MT; Winterhalter KH; Zimmermann DR
J Biol Chem; 1998 Jun; 273(25):15758-64. PubMed ID: 9624174
[TBL] [Abstract][Full Text] [Related]
35. Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4.
Sandy JD; Westling J; Kenagy RD; Iruela-Arispe ML; Verscharen C; Rodriguez-Mazaneque JC; Zimmermann DR; Lemire JM; Fischer JW; Wight TN; Clowes AW
J Biol Chem; 2001 Apr; 276(16):13372-8. PubMed ID: 11278559
[TBL] [Abstract][Full Text] [Related]
36. Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain.
Ang LC; Zhang Y; Cao L; Yang BL; Young B; Kiani C; Lee V; Allan K; Yang BB
J Neuropathol Exp Neurol; 1999 Jun; 58(6):597-605. PubMed ID: 10374750
[TBL] [Abstract][Full Text] [Related]
37. Mapping of a defined neurocan binding site to distinct domains of tenascin-C.
Rauch U; Clement A; Retzler C; Fröhlich L; Fässler R; Göhring W; Faissner A
J Biol Chem; 1997 Oct; 272(43):26905-12. PubMed ID: 9341124
[TBL] [Abstract][Full Text] [Related]
38. Versican: signaling to transcriptional control pathways.
Rahmani M; Wong BW; Ang L; Cheung CC; Carthy JM; Walinski H; McManus BM
Can J Physiol Pharmacol; 2006 Jan; 84(1):77-92. PubMed ID: 16845893
[TBL] [Abstract][Full Text] [Related]
39. Versican/PG-M G3 domain promotes tumor growth and angiogenesis.
Zheng PS; Wen J; Ang LC; Sheng W; Viloria-Petit A; Wang Y; Wu Y; Kerbel RS; Yang BB
FASEB J; 2004 Apr; 18(6):754-6. PubMed ID: 14766798
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of the C-terminal PG-M/versican domain impairs growth of tumor cells by intervening in the interaction between epidermal growth factor receptor and beta1-integrin.
Wu Y; Chen L; Cao L; Sheng W; Yang BB
J Cell Sci; 2004 May; 117(Pt 11):2227-37. PubMed ID: 15126624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
